[go: up one dir, main page]

PH12014500544B1 - Dengue-virus serotype neutralizing antibodies - Google Patents

Dengue-virus serotype neutralizing antibodies

Info

Publication number
PH12014500544B1
PH12014500544B1 PH1/2014/500544A PH12014500544A PH12014500544B1 PH 12014500544 B1 PH12014500544 B1 PH 12014500544B1 PH 12014500544 A PH12014500544 A PH 12014500544A PH 12014500544 B1 PH12014500544 B1 PH 12014500544B1
Authority
PH
Philippines
Prior art keywords
dengue
neutralizing antibodies
virus serotype
virus
serotype neutralizing
Prior art date
Application number
PH1/2014/500544A
Other versions
PH12014500544A1 (en
Inventor
NUEGOONPIPAT Atchareeya A-
Surapee Anantapreecha
Panadda Dhepakson
Kazuyoshi Ikuta
Motoki Kuhara
Yoshinobu Okuno
Apichai Prachasuphap
Pongrama Ramasoota
Tadahiro Sasaki
Pathom Sawanpanyalert
Chayanee Setthapramote
Aree Thattiyaphong
Original Assignee
Dept Of Medical Sciences Dmsc
Mahidol Univ
Medical & Biol Lab Co Ltd
Univ Osaka
Univ Osaka Res Found For Microbial Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dept Of Medical Sciences Dmsc, Mahidol Univ, Medical & Biol Lab Co Ltd, Univ Osaka, Univ Osaka Res Found For Microbial Diseases filed Critical Dept Of Medical Sciences Dmsc
Publication of PH12014500544A1 publication Critical patent/PH12014500544A1/en
Publication of PH12014500544B1 publication Critical patent/PH12014500544B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Materials and methods are provided for treating dengue infections. Human monoclonal antibodies against all serotypes of dengue virus are also provided. Methods of using human monoclonal antibodies to neutralize all dengue-virus serotypes are provided using patients' peripheral blood lymphocytes.
PH1/2014/500544A 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies PH12014500544B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532605P 2011-09-09 2011-09-09
US201161532671P 2011-09-09 2011-09-09
PCT/JP2012/005699 WO2013035345A2 (en) 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies

Publications (2)

Publication Number Publication Date
PH12014500544A1 PH12014500544A1 (en) 2014-04-21
PH12014500544B1 true PH12014500544B1 (en) 2019-03-13

Family

ID=47116163

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2014/500544A PH12014500544B1 (en) 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies

Country Status (5)

Country Link
AU (1) AU2012305807B2 (en)
MY (1) MY170725A (en)
PH (1) PH12014500544B1 (en)
SG (1) SG11201400100SA (en)
WO (1) WO2013035345A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6764348B2 (en) 2014-02-11 2020-09-30 ビステラ， インコーポレイテッド Antibody molecules against dengue virus and their use
CN105137068B (en) * 2015-07-24 2017-03-01 鲁东大学 Florfenicol Site Detection reagent paper and its preparation, using method
CN105004860B (en) * 2015-07-24 2016-09-21 鲁东大学 Florfenicol rapid detection kit and its preparation and use method
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
CN109929033B (en) * 2019-03-15 2020-06-02 中国人民解放军军事科学院军事医学研究院 A human antibody that specifically binds four serotypes of dengue virus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
PT752248E (en) 1992-11-13 2001-01-31 Idec Pharma Corp THERAPEUTIC APPLICATION OF QUIMERIC ANTIBODIES AND RADIOACTIVELY MARKING OF ANTIGENES OF RESTRICTED DIFFERENTIATION OF HUMAN LYMPHOCYTE B FOR THE TREATMENT OF B-CELL LYMPHOMA
DE4337197C1 (en) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Process for the selective preparation of hybridoma cell lines which produce monoclonal antibodies with high cytotoxicity against human CD16 antigen, and the preparation of bispecific monoclonal antibodies using such monoclonal antibodies and the CD30-HRS-3 antibody for therapy of human tumours
WO1998047343A2 (en) 1997-04-04 1998-10-29 Biosite Diagnostics, Inc. Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages
EP1597280B2 (en) * 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
CN101466828B (en) * 2006-04-13 2011-12-21 株式会社医学生物学研究所 Fusion partner cells
EP2144931A2 (en) * 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
WO2010073647A1 (en) * 2008-12-25 2010-07-01 国立大学法人大阪大学 Human anti-human influenza virus antibody
SG173482A1 (en) * 2009-02-10 2011-09-29 Univ Nanyang Tech Antibodies for diagnosis and treatment of flaviviral infections

Also Published As

Publication number Publication date
WO2013035345A2 (en) 2013-03-14
MY170725A (en) 2019-08-27
AU2012305807A8 (en) 2014-03-13
SG11201400100SA (en) 2014-06-27
PH12014500544A1 (en) 2014-04-21
AU2012305807B2 (en) 2015-08-20
WO2013035345A3 (en) 2013-09-06
AU2012305807A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
PH12017501075A1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
EA201490004A1 (en) BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES
PH12016500859B1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EA201300016A1 (en) HUMAN ANTIBODY CONJUGATES AGAINST TISSUE FACTOR WITH DRUGS
JOP20210044A1 (en) Anti-CD38 . antibody
UA112288C2 (en) Antibody forvulation and therapeutic regimens
MX2012001882A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use.
IN2014DN07149A (en)
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
MD20140035A2 (en) Method of treatment of viral hepatitis C
UA109658C2 (en) ANTIBODY AGAINST CGRP
PH12015501558A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
MX350200B (en) Human antibodies and antibody-drug conjugates against cd74.
DE602007013618D1 (en) ANTIBODIES TO THE HUMAN CYTOMEGALIE VIRUS (HCMV)
EA201590562A1 (en) БЕНЗАМИДЫ
MX2015008534A (en) ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF.
BR112013032456A2 (en) anti-cxcr4 antibody with effector functions and its use for cancer treatment
EA201300132A1 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV
PH12014500544B1 (en) Dengue-virus serotype neutralizing antibodies
MX356745B (en) A human monoclonal antibody against the vp1 protein of jc virus.
UA109148C2 (en) ANTIBODY COMPOSITES AGAINST VEGFR-3
EA201390417A1 (en) ANTI-DIABETIC SOLID PHARMACEUTICAL COMPOSITIONS
MX2013010367A (en) Compositions and methods for the therapy and diagnosis of influenza.
MX2013009529A (en) Treatment of fistulizing crohn's disease.
WO2012119989A3 (en) Antibodies against cadmi for the diagnosis and treatment of cancer